Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from HIMS

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Barchart

MarketBeat Week in Review – 02/17 - 02/21

Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news

MarketBeat

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

MarketBeat

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

MarketBeat

Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

3 Telemedicine Stocks Making Healthcare More Accessible

The telemedicine industry is transforming healthcare with digital platforms, growing consumer demand, and innovative care delivery models. As the sector evolves, telemedicine stocks like Doximity (DOCS), Hims & Hers Health (HIMS), and GoodRx Holdings (GDRX) are well-positioned to capitalize on this trend. Read on….

StockNews.com

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

MarketBeat

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

MarketBeat

3 Digital Health Companies Enhancing Patient Engagement

The digital health industry has experienced impressive growth, driven by rising healthcare demands, digitalization, and technological innovations. Amid this, Hims & Hers Health (HIMS), GoodRx Holdings (GDRX), and Talkspace (TALK) are strategically positioned to thrive in the sector, making them attractive investment opportunities. Read on….

StockNews.com

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Spotlight on Hims & Hers Health: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Hims Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HIMS usually suggests something big…

Barchart

Is Hims & Hers Stock a Buy for GLP-1 Upside?

Hims & Hers is a digital health company that is firing on all cylinders, while improving its profit margins at a robust pace.

Barchart

After Doubling in the Past 6 Months, Will Hims & Hers Health Stock Continue Higher?

Telehealth company Hims & Hers is trading near record highs after issuing strong guidance for the full year ahead. With the stock up nearly 145% in the last six months, how much more upside is left for HIMS?

The Independent UK

Subscription-based care moves beyond peddling birth control and helping with hair loss

Online, direct-to-consumer health care has grown well beyond its roots mostly treating hair loss and acne or selling birth control pills

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

HIMS Associate Professor, earlier suspended on charges of misconduct, appointed District Surgeon in Hassan

Dr. H.C. Lokesh appointed District Surgeon of Sri Chamarajendra Hospital in Hassan after being reinstated in August 2022.

The Hindu

MBBS classes will start in new building of Haveri Institute of Medical Sciences, says Minister Shivanand Patil

Minister for Textiles, Sugarcane Development and Sugar and district-in-charge for Haveri Shivanand Patil announced that the classes of the first year MBBS course would be held at the new building of Haveri Institute of Medical Sciences and Hospital from September.

Broadcasting & Cable

Fubo’s Maximum Effort Channel Brings Back ALF in Series, Branded Content

Mint Mobile, Fubo, Hims, MNTN, Ring get messages from Paul Fusco’s furry alien

The Hindu

Tension at NICU in Hassan Institute of Medical Sciences after stabiliser blast

Tension prevailed in the Neonatal Intensive Care Unit (NICU) of the Hassan Institute of Medical Sciences (HIMS) in Hassan on Sunday when smoke covered the premises broke out following a stabiliser blast.

StockNews.com

Insider Trading Picking Up For HIMS, Should You Buy?

Shares of multi-specialty healthcare company Hims & Hers Health (HIMS) gained more than 25% over the past month, with increased insider trading sparking investor interest. However, given its bleak financials, is the stock a buy now? Read more to find out.

StockNews.com

After Plummeting from Covid-Induced Highs, is Now a Good Time to Scoop Up Telehealth Stocks?

Telehealth stocks have declined from the Covid-induced highs and are expected to plunge further due to the nation’s return to normalcy. Moreover, the current macroeconomic headwinds are expected to put added pressure on telehealth companies Teladoc Health (TDOC), American Well (AMWL), Hims & Hers Health (HIMS), iRhythm Technologies (IRTC), and…

Benzinga

Hims & Hers Health's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Hims & Hers Health (NYSE:HIMS) posted sales of $101.31 million. Earnings were up 47.85%, but Hims & Hers Health still reported an overall loss of $16.25 million.

1 … 3 4 5 6

People

Donald Trump

202,247 stories

Dipanjan BanchurSince

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.